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performed per sample for the serum, but that there is minimal
loss of the BAP analyte out to 5 freeze/thaw cycles for the SF.
Conclusions: The Metra® BAP assay is a reproducible and valid
assay for use with equine serum and synovial fluid.
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Purpose: Synovial fluid as a lubricant of knee joints has its vis-
cosity depending on the molecular weight (MW) and concentra-
tion of hyaluronan (HA). HA concentration in synovial fluid have
been frequently reported, but there are few reports analysing
MW of HA in synovial fluid of patients with osteoarthritis(OA).
The purpose of this study was to measure the MW of HA by
using SEC-LALLS (Size-exclusion chromatography(SEC)- a low-
angle laser light scattering(LALLS)) system, and to evaluate the
change in MW of HA after glucosamine administration.
Methods: Five knee OA patients(3 men, 2 women, mean age:
60.6 years) recieved 1.5g of glucosamine hydrochloride per day
for one month. Synovial fluid samples were collected before and
after glucosamine administration.The SEC-LALLS system(Asahi
Techneion) was used to determine the MW of HA. First,the HA
fraction was separated by using SEC system and then the MW of
HA was calculated by measuring LALLS and refractive index(RI).
Triple Detector Array (Viscotek Corporation)which has a LALLS
detector, a RI detector and a viscometer was utilized for the
measurement. Before analyzing HA samples, the accuracy of the
SEC-LALLS system was calibrated with three HA standards (su-
venyl, artz and HA(lowMW-type)(Seikagaku Corporation). (MW
of suvenyl, artz and low MW HA: 1900-2500, 600-1200 and
100-150(kDa)) Furthermore, hyaluronidase treatment was also
done for the confirmation of HA. As a clinical test,visual analogue
scale (VAS) of OA patients was also measured.
Results: The SEC-LALLS system was effective in the MW mea-
surement of HA. MW of three kinds of HA standards,suvenyl,
artz and HA(lowMW-type)were estimated as 2400, 870 and
160(kDa)respectively. It was succeeded that HA fraction was
isolated and identified from synovial fluid samples using this sys-
tem with high sensitivity. As a proof of HA, it was demonstrated
that this peak fraction from HA disappeared after hyaluronidase
digestion. The MW of HA (mean±SD) in synovial fluid of OA pa-
tients increased from 4350±1170 to 5030±1280(kDa) after glu-
cosamine treatment. VAS for knee pain(mean±SD) decreased
significantly from 4.8±1.3 to 1.7±1.0.
Conclusions: We could separate HA from human synovial fluid
and determine the MW of HA with high sensitivity by using
the SEC-LALLS system. A change in MW of HA was detected
after glucosamine treatment, and knee pain was also alleviated.
Therefore these changes suggested glucosamine had an effect
on the metabolism of HA. Estimating the change in MW of
HA by this system may be useful for monitoring a treatment
process of symptom modifying OA drugs. Nevertheless, further
clinical studies in a lager scale are needed to investigate the
improvements in clinical symptoms with alterations in MW of HA
in synovial fluid.
Bone Biology
P117
CHONDROGENIC MARKERS ARE EXPRESSED AND
REGULATED IN BONE AND CORRELATE WITH BONE
MASS
N. Kulkarni1, T. Wei1, M. Schreiweis1, K. Brune1,
T. Christopher1, J. Wolos1, A. Harvey1, S. Chandrasekhar1,
M. Carozza1, T. Engler1, T. Martin2, H. Bryant1, Y. Ma1,
P. Mitchell1, J. Hale1, J. Onyia1
1Lilly Research Labs, Indianapolis, IN, 2SVIMR, Fitzroy, Australia
Purpose: The expression of chondrogenic markers (collagen
type II and X, aggrecan, cartilage oligomeric matrix protein)
are largely restricted to cartilage and play a role in cartilage
metabolism and function. Recently we have shown that (unpub-
lished) these markers are also expressed in adult rat bone and
primary osteoblasts. In this study, we sought to confirm their
expression at mRNA and protein level in bone; compare the
temporal expression of these markers to established osteogenic
markers in ovariectomized (Ovx) rat model of osteopenia; and
evaluate the regulation of these markers upon treatment with
known bone anabolic agents.
Methods: Six-month old, female Sprague Dawley rats (n=10),
were Ovx or sham-operated. The animals were sacrificed at 2,
4, 6, 8 and 12 weeks post-ovx and left femur was analyzed
for BMD and BMC using quantitative computerized tomography.
The right femur (distal metaphysis without epiphysis) was pro-
cessed for mRNA analysis of osteogenic (collagen α1 (I), α2
(I), α1 (V), osteocalcin, osteonectin, bone sialoprotein, biglycan,
alphos) and chondrogenic (collagen α1 (II), aggrecan, COMP,
Cdrap) markers by quantitative real-time PCR (qPCR). Biochem-
ical markers of bone and cartilage turnover (collagen type I and
II degradation products in the serum CTX-I and CTX-II) were
measured by ELISA. Type II collagen and aggrecan proteins
in bones were confirmed by Western analysis and LC/MS. To
assess the effects of bone anabolic agents on the regulation
of bone and cartilage markers, Ovx rats permitted to lose bone
for one month were treated with PTH (1-38) at 10 μg/kg, sc
or 603281-31-8 at 3mg/kg/d (GSK-3 inhibitor), po for 60 days.
Twenty-four hr after the last treatment, RNA from distal femur
metaphysis was analyzed by qPCR to assess the expression
levels of these marker genes. Pearson correlation coefficients
were used to measure correlations between gene expression
and phenotypic parameters
Results: qPCR confirmed the expression of the chondrogenic
markers in bone and in primary osteoblasts. LC/MS and Western
analysis validated the presence of type II collagen and aggrecan
proteins in both metaphyseal and diaphyseal bone. Ovx for 12
weeks resulted in significantly lower BMD at whole and distal
femur (10-15%) relative to sham controls. This was associated
with a temporal decrease in the expression levels of chondro-
genic markers (2 to 5-fold) with optima observed at 8-12 weeks
post-ovx. In contrast, the expression levels of osteogenic mark-
ers steadily increased with maxima observed at 6 weeks (1.2
to 4-fold) followed by decline below sham levels. The levels of
CTX-I and CTX-II were increased in the serum of Ovx rats and
returned to near sham levels by 12 weeks. The magnitude of
change in CTX-II levels (4.8-fold) was > CTX-I (1.9-fold). Treat-
ment with bone anabolics, PTH or GSK-3 inhibitor restored bone
mass in Ovx rats and was associated with a robust increase in
the gene expression of chondrogenic (1.6 to 4.7-fold) compared
to osteogenic markers (1.1 to 1.8-fold). Interestingly, overall the
chondrogenic markers showed a better correlation (r=0.71) to
BMD & BMC compared to osteogenic markers (r<0.5).
Conclusions: These results demonstrate the presence and the
regulation of chondrogenic markers in rat long bone. This sug-
gests either the continued presence of cartilage in adult rat bone
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or that these markers are not necessarily cartilage specific and
could play similar or novel role in bone remodeling. Furthermore,
the robust regulation of chondrogenic markers in bone and their
good correlation to BMD & BMC suggest that they could be good
predictors of disease and treatment outcomes.
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Purpose: There is consensus that osteoarthritis (OA) is char-
acterized by subchondral bone thickening, accompanied by an
increased osteoid volume and a low mineralization. Until now,
phenotypical changes occurring in osteoblasts from the sclerotic
subchondral bone remains unexplored. This work was designed
to compare gene expression in osteoblasts coming from the
sclerotic and non sclerotic zones of human OA subchondral
bone.
Methods: Human osteoblasts were isolated from sclerotic or
non sclerotic areas of OA subchondral bone. They were cultured
for 12 days in monolayer in a differentiation medium composed
of 2% Ultroser G as serum substitute, 2 mM proline, 50 micro-
gram/ml ascorbic acid and 10-8 M 1,25 dihydroxycalciferol. At
the end of this differentiation period, gene expression in sclerotic
or non sclerotic osteoblasts was compared. Tissue non specific
alkaline phosphatase (TNAP), osteocalcin (OC), transforming
growth factor -beta1 (TGF-beta1), osteopontin (OPN), bone sialo-
protein (BSP), vascular endothelial growth factor (VEGF), matrix
metalloproteinase (MMP)-13, parathormone receptor (PTH-R),
transglutaminase (TG)-2, factor XIIIA (FXIIIA), plasma cell mem-
brane glycoprotein 1 (PC-1) and Ank mRNA levels were quan-
tified using real time RT-PCR. Transglutaminase and nucleotide
triphosphate pyrophosphohydrolase (NTPPPH) activities were
also quantified by enzymatic assays.
Results: MMP-13 (21-fold; p<0.001), OPN (2.8-fold; p<0.001),
TNAP (2-fold, p<0.001), OC (2-fold, p<0.001), TGF-beta1 (1.4-
fold, p<0.01) and VEGF (1,5-fold; p<0.001) gene expression
was significantly higher in sclerotic osteoblasts than in non scle-
rotic cells. In contrast, PTH-R (-37%, p<0.001), PC-1 (-22%,
p <0.01), Ank (-24%, p<0.01) genes were depressed in scle-
rotic osteoblasts compared with non sclerotic cells. Finally, BSP,
TG2 and FXIIIA mRNA levels were similar in sclerotic and non
sclerotic osteoblasts. Transglutaminase activity was increased by
53% in sclerotic osteoblasts (p<0.001), while NTPPPH activity
was decreased by 32% (p<0.001).
Conclusions: Osteoblasts from the sclerotic subchondral bone
showed an altered phenotype characterized by the overexpres-
sion of genes limiting bone mineralization (OPN, PC-1, ...), on
one hand, and genes promoting osteoid matrix accumulation
(TGF-beta1, OC) on the other hand. These findings suggest that
osteoblasts may contribute to subchondral bone sclerosis and as
such constitute a potential target for future OA therapies.
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Purpose: Wnts are secreted signalling molecules, traditionally
associated with developmental processes. Various members of
the Wnt signalling pathway have been implicated in osteogenic
differentiation and high and low bone mass phenotypes. In os-
teoarthritis (OA) there is a massive proliferation of hypominer-
alized trabecular bone. Our hypothesis is that musculoskeletal
cells revert to an earlier, developmental, phenotype and attempt
to produce new matrix inappropriately. We have performed a
pilot study to analyze the role of Wnt signalling in OA by profiling
the expression of Wnt pathway genes in osteoblasts. Bone from
patients with osteoporosis (OP), displaying a low bone mass
phenotype, were used for comparison.
Methods: Femoral heads were obtained from consenting pa-
tients undergoing a total hip replacement for OA (N=5, aged
55-86) or a hemiarthroplasty following a fractured neck of femur
for OP (N=5, aged 68-92). Primary osteoblasts were grown from
bone chips. Total RNA was isolated from cells using Trizol (In-
vitrogen) followed by RNeasy purification (Qiagen) and prepared
for application as biotinylated cRNA to a Wnt pathway Oligo GE
Array (Super Array Biosciences) containing oligo-probes for 128
Wnt-related and housekeeping genes. Intensities were corrected
for background and normalised using the inter-quartile median.
Mean values of signal intensities (medians if not normally dis-
tributed) were found for each disease group, and compared
using analysis of variance. The most highly expressed 30 genes
(∼25%) were examined in each group and the Log2(OA/OP) (sig-
nal log ratio, SLR) calculated and deemed important if greater
than 0.5 or less than -0.5.
Results: The Wnt signalling pathway was clearly active in os-
teoblasts in both dseases. Expression levels for the top 30 genes
were significantly greater than those for the lowest expressed
gene (p<0.05, pairwise comparison, ANOVA on ranks). WISP2,
GSK3A, AES and DVL1 were among the most highly expressed
genes in both diseases and 27 of the top 30 were common to both
groups. High SLR values were found in 7 of these genes, though
no differences in signal between the groups reached statistical
significance at p<0.05. Secreted frizzled related proteins SFRP4
(SLR 0.84) (p=0.056), and SFRP3/FRZB (0.59) were higher in
OA than OP. The Na/H transporter regulator SLC9A3R1/EBP50
(-0.85) and transducin-like enhancers of split TLE1 (-0.51) and
TLE3 (-0.52) were more highly expressed in OP than OA. Of the
Wnt proteins, Wnts 16, 1 and 5a were the most highly expressed
but only WNT5A showed any differential expression with an SLR
of 0.45 (p=0.057).
Conclusions: Wnt signalling is clearly active in elderly bone.
Secreted frizzled-related proteins are extracellular inhibitors of
Wnt signalling and, of particular interest, FRZB has been iden-
tified as a candidate in genetic linkage studies of OA. How-
ever, lower levels of TLEs in OA would indicate higher levels
of gene transcription through the canonical signalling pathway.
The balance between these processes needs further investiga-
tion. Dishevelled-dependent Wnt5a signalling can be transduced
through the RHOA pathway, affecting the cytoskeleton and com-
mitment to cell lineage, and via MAP kinases through the JNK
pathway affecting gene transcription. Higher levels could be a
factor underlying the cellular changes seen in OA.
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Purpose: Aseptic osteonecrosis of the femoral head (ONFH) is
a painful and progressive disorder of the hip, which often leads
to collapse and disabling secondary osteoarthritis of the hip joint.
